<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02336854</url>
  </required_header>
  <id_info>
    <org_study_id>111HPS14027</org_study_id>
    <nct_id>NCT02336854</nct_id>
  </id_info>
  <brief_title>Tacrobell tab_Phase1_PK</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <brief_summary>
    <textblock>
      A randomized, open-label, two-way crossover study to assess the tolerability and
      pharmacokinetics of Tacrobell® Tab. and Prograf® Cap. after a single oral dose in healthy
      male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2015</start_date>
  <completion_date type="Actual">March 19, 2015</completion_date>
  <primary_completion_date type="Actual">February 2, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>up to 96 hous postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 96 hous postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>up to 96 hous postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>up to 96 hous postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>up to 96 hous postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>up to 96 hous postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Immunosuppressant(Organ Transplantation, RA)</condition>
  <arm_group>
    <arm_group_label>Tacrobell tab. 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg/tablet, PO, 1 tablet once daily for Period I &amp; II D1(crossover)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prograf cap. 2mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1mg/capsule, PO, 2 capsule once daily for Period I &amp; II D1(crossover)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrobell tab. 2mg</intervention_name>
    <arm_group_label>Tacrobell tab. 2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf cap. 2mg</intervention_name>
    <arm_group_label>Prograf cap. 2mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Understand the requirements of the study and voluntarily consent to participate in the
             study.

          2. Healthy male volunteer in the age between 20 and 45 years old.

          3. Body weight ≥ 55 kg and 30.0kg/m2 ≥ BMI ≥ 18.0kg/m2

        Exclusion Criteria:

          1. presence or a history of clinically significant cardiovascular, renal, hepatic,
             pulmonary, metabolic, endocrine, hematological, gastrointestinal, neurological,
             psychiatric or other diseases

          2. any chronic disease which might interfere with resorption, distribution, metabolism or
             excretion of the drug, or major surgery of the gastrointestinal tract except for
             appendectomy

          3. any history of drug hypersensitivity (especially to the active and inactive
             ingredients of the tacrolimus preparation)

          4. administration of cyclosporine or Bosentan

          5. administration of potassium sparing diuretic

          6. Subjects with galactose intolerance, Lapp lactase deficiency or glucose-galactose
             malabsorption

          7. SBP &gt; 150 mmHg or&lt; 90 mmHg

          8. DBP &gt; 100 mmHg or &lt; 50 mmHg

          9. positive serologic findings for human immunodeficiency virus (HIV) antibodies,
             hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies, RPR

         10. AST or ALT &gt; 1.5*ULN, e-GFR &lt; 80 mL/min

         11. history of drug abuse or positive drug screening test

         12. intake or administration of any ethical or herbal medication medication within 2
             weeks, intake or administration of any OTC or vitamin preparations

         13. medication with metabolizing enzyme inducers or inhibitors such as barbitals within 1
             month before first dosing

         14. administration of another study medications within 3 months before first dosing

         15. blood donation in 2 months, component blood donation within 1 month or blood
             transfusion before first dosing

         16. Alcohol &gt; 21 units/week or cannot stop drinking during the study

         17. Cigarette &gt; 10 cigarettes/day or cannot stop smoking during hospitalization

         18. consumption of beverages or food containing caffeine(e.g.coffee, tea) during
             hospitalization

         19. consumption of grapefruit or food containing grapefruit during hospitalization

         20. Not eligible to participate for the study at the discretion of investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>January 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

